methyl 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylate | 209330-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylate
• 英文别名: 2-chloro-5,6,7,8-tetrahydro-quinoline-4-carboxylic acid methyl ester；2-Chlor-5,6,7,8-tetrahydro-chinolin-4-carbonsaeure-methylester
• CAS: 209330-14-3
• 化学式: C₁₁H₁₂ClNO₂
• 分子量: 225.675
• InChiKey: HRWPYTCDFQESAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylate 在 一水合肼 作用下， 以 乙醇 、 正丁醇 为溶剂， 反应 17.0h， 生成 2-(3-methylanilino)-5,6,7,8-tetrahydroquinoline-4-carbohydrazide
  参考文献：
  名称：

  2-氯-和2-芳基氨基-5,6-三亚甲基和5,6-四亚甲基异烟酸的2-亚芳基-和2-(5-硝基呋喃基)酰肼的合成和抗菌活性

  摘要：

  此前，我们报道了一系列 2-芳基氨基 5,6,7,8-四氢喹啉-4-羧酸的异丙基酰胺的合成和表征，具有抗炎和镇痛活性 [1]。此类的另一种活性化合物是 5,6,7,8-四氢喹啉 4-羧基酰肼，已知具有抗结核特性 [2]。这项工作的目的是在 2-氯和 2-芳氨基-5,6 三（四）亚甲基异烟酸的亚芳基和 5-硝基呋喃基酰肼中寻找具有抗菌活性的化合物 最初的化合物是甲酯 [2] 和乙酯（ I a Ic ) 通过 5,6 三亚甲基和 5,6-四亚甲基-2-羟基异烟酸与五氯化磷和相应的醇的连续反应获得。先前的研究表明，在 DMF 中沸腾 4 17 小时期间，酯 Ib 中的卤素原子不会被芳基氨基亲核置换（我们报道了 2-氯-5,6,7,8-四氢喹啉的低迁移率- 4-羧酸异丙基酰胺）[1]。该反应仅通过将这些酯与芳胺盐酸盐在无水丁醇中煮沸 12 小时进行，导致 2-芳氨基-5,6,7,8-四氢喹啉-4 羧酸酯

  DOI：

  10.1007/bf02464164
• 作为产物：
  描述：

  2-氧代环己烷乙醛酸乙酯 在 乙醇 、 五氯化磷 、 硫酸 、 sodium ethanolate 、 三氯氧磷 作用下， 生成 methyl 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylate
  参考文献：
  名称：

  实验性结核菌糖化学III。衍生物2-甲基-异烟酸酯

  摘要：

  合成了约52个2-甲基异烟酸酰肼衍生物，并测试了它们的抗结核作用。通过2-甲基异烟酰胺酰肼与醛，酮和羧酸氯化物的反应，通过2-甲基异烟酰胺酰氯与二烷基化肼的缩合，以及2-甲基异烟碱酰肼的氢化来制备衍生物。

  DOI：

  10.1002/hlca.19550380425

文献信息

• Discovery of Inducible Nitric Oxide Synthase (iNOS) Inhibitor Development Candidate KD7332, Part 1: Identification of a Novel, Potent, and Selective Series of Quinolinone iNOS Dimerization Inhibitors that are Orally Active in Rodent Pain Models
  作者：Céline Bonnefous、Joseph E. Payne、Jeffrey Roppe、Hui Zhuang、Xiaohong Chen、Kent T. Symons、Phan M. Nguyen、Marciano Sablad、Natasha Rozenkrants、Yan Zhang、Li Wang、Daniel Severance、John P. Walsh、Nahid Yazdani、Andrew K. Shiau、Stewart A. Noble、Peter Rix、Tadimeti S. Rao、Christian A. Hassig、Nicholas D. Smith

  DOI：10.1021/jm900173b

  日期：2009.5.14

  There are three isoforms of dimeric nitric oxide synthases (NOS) that convert arginine to citrulline and nitric oxide. Inducible NOS is implicated in numerous inflammatory diseases and, mote recently, in neuropathic pain states. The majority of existing NOS inhibitors are either based on the structure of arginine or are substrate competitive. We describe the identification from an ultra high-throughput screen of a novel series of quinolinone small molecule, nonarginine iNOS dimerization inhibitors. SAR studies on the screening hit, coupled with an in vivo lipopolysaccharide (LPS) challenge assay measuring plasma nitrates and drug levels, rapidly led to the identification of compounds 12 and 42-potent inhibitors of the human and mouse iNOS enzyme that were highly selective over endothelial NOS (eNOS). Following oral dosing, compounds 12 and 42 gave a statistical reduction in pain behaviors in the mouse formalin model, while 12 also statistically reduced neuropathic pain behaviors in the chronic constriction injury (Bennett) model.
• Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents
  作者：Balakrishna Dulla、Baojie Wan、Scott G. Franzblau、Ravikumar Kapavarapu、Oliver Reiser、Javed Iqbal、Manojit Pal

  DOI：10.1016/j.bmcl.2012.05.096

  日期：2012.7

  A series of fused and functionalized pyridine derivatives were designed, synthesized and tested for their potential antitubercular properties. All these novel compounds were prepared by using multistep methods involving the construction of pyridine ring as a key synthetic step. Some of these compounds were found to be interesting when tested for their antitubercular properties in vitro and one of them appeared as an attractive and potential antitubercular agent. (C) 2012 Elsevier Ltd. All rights reserved.